Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib Phase I in Advanced Solid Tumors
NCT02122809Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chiauranib in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Dose-Limiting Toxicity and Number of Adverse Events at 8 months. Started Feb 2014; status: completed.
02
Drugs
chiauranib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02122809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122809.